FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593663511> ?p ?o ?g. }

• W2593663511 endingPage "e1002248" @default.
• W2593663511 startingPage "e1002248" @default.
• W2593663511 abstract "Chronic liver scarring from any cause leads to cirrhosis, portal hypertension, and a progressive decline in renal blood flow and renal function. Extreme renal vasoconstriction characterizes hepatorenal syndrome, a functional and potentially reversible form of acute kidney injury in patients with advanced cirrhosis, but current therapy with systemic vasoconstrictors is ineffective in a substantial proportion of patients and is limited by ischemic adverse events. Serelaxin (recombinant human relaxin-2) is a peptide molecule with anti-fibrotic and vasoprotective properties that binds to relaxin family peptide receptor-1 (RXFP1) and has been shown to increase renal perfusion in healthy human volunteers. We hypothesized that serelaxin could ameliorate renal vasoconstriction and renal dysfunction in patients with cirrhosis and portal hypertension.To establish preclinical proof of concept, we developed two independent rat models of cirrhosis that were characterized by progressive reduction in renal blood flow and glomerular filtration rate and showed evidence of renal endothelial dysfunction. We then set out to further explore and validate our hypothesis in a phase 2 randomized open-label parallel-group study in male and female patients with alcohol-related cirrhosis and portal hypertension. Forty patients were randomized 1:1 to treatment with serelaxin intravenous (i.v.) infusion (for 60 min at 80 μg/kg/d and then 60 min at 30 μg/kg/d) or terlipressin (single 2-mg i.v. bolus), and the regional hemodynamic effects were quantified by phase contrast magnetic resonance angiography at baseline and after 120 min. The primary endpoint was the change from baseline in total renal artery blood flow. Therapeutic targeting of renal vasoconstriction with serelaxin in the rat models increased kidney perfusion, oxygenation, and function through reduction in renal vascular resistance, reversal of endothelial dysfunction, and increased activation of the AKT/eNOS/NO signaling pathway in the kidney. In the randomized clinical study, infusion of serelaxin for 120 min increased total renal arterial blood flow by 65% (95% CI 40%, 95%; p < 0.001) from baseline. Administration of serelaxin was safe and well tolerated, with no detrimental effect on systemic blood pressure or hepatic perfusion. The clinical study's main limitations were the relatively small sample size and stable, well-compensated population.Our mechanistic findings in rat models and exploratory study in human cirrhosis suggest the therapeutic potential of selective renal vasodilation using serelaxin as a new treatment for renal dysfunction in cirrhosis, although further validation in patients with more advanced cirrhosis and renal dysfunction is required.ClinicalTrials.gov NCT01640964." @default.
• W2593663511 created "2017-03-16" @default.
• W2593663511 creator A5003818035 @default.
• W2593663511 creator A5006457421 @default.
• W2593663511 creator A5011316383 @default.
• W2593663511 creator A5013279353 @default.
• W2593663511 creator A5016791237 @default.
• W2593663511 creator A5018412105 @default.
• W2593663511 creator A5020204477 @default.
• W2593663511 creator A5021746061 @default.
• W2593663511 creator A5028036727 @default.
• W2593663511 creator A5028140950 @default.
• W2593663511 creator A5032871928 @default.
• W2593663511 creator A5040740891 @default.
• W2593663511 creator A5048053538 @default.
• W2593663511 creator A5051001507 @default.
• W2593663511 creator A5053519976 @default.
• W2593663511 creator A5065112664 @default.
• W2593663511 creator A5068071602 @default.
• W2593663511 creator A5068122614 @default.
• W2593663511 creator A5075786077 @default.
• W2593663511 creator A5080104851 @default.
• W2593663511 creator A5080575738 @default.
• W2593663511 creator A5081449769 @default.
• W2593663511 creator A5084082130 @default.
• W2593663511 creator A5085190060 @default.
• W2593663511 creator A5089067662 @default.
• W2593663511 creator A5090434252 @default.
• W2593663511 date "2017-02-28" @default.
• W2593663511 modified "2023-10-17" @default.
• W2593663511 title "Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial" @default.
• W2593663511 cites W1519148279 @default.
• W2593663511 cites W1573768413 @default.
• W2593663511 cites W1578969802 @default.
• W2593663511 cites W1638167482 @default.
• W2593663511 cites W1968958833 @default.
• W2593663511 cites W1971666673 @default.
• W2593663511 cites W1978909118 @default.
• W2593663511 cites W1984223131 @default.
• W2593663511 cites W1984606464 @default.
• W2593663511 cites W1992177436 @default.
• W2593663511 cites W2007670274 @default.
• W2593663511 cites W2008373249 @default.
• W2593663511 cites W2012746560 @default.
• W2593663511 cites W2019820739 @default.
• W2593663511 cites W2026218677 @default.
• W2593663511 cites W2046700466 @default.
• W2593663511 cites W2047985986 @default.
• W2593663511 cites W2055898043 @default.
• W2593663511 cites W2058332877 @default.
• W2593663511 cites W2065882730 @default.
• W2593663511 cites W2072271483 @default.
• W2593663511 cites W2073507516 @default.
• W2593663511 cites W2074938781 @default.
• W2593663511 cites W2087484885 @default.
• W2593663511 cites W2088861312 @default.
• W2593663511 cites W2093985186 @default.
• W2593663511 cites W2097143107 @default.
• W2593663511 cites W2103472550 @default.
• W2593663511 cites W2104610466 @default.
• W2593663511 cites W2107062590 @default.
• W2593663511 cites W2108419567 @default.
• W2593663511 cites W2110280698 @default.
• W2593663511 cites W2117367934 @default.
• W2593663511 cites W2120200350 @default.
• W2593663511 cites W2126087368 @default.
• W2593663511 cites W2127057614 @default.
• W2593663511 cites W2133739113 @default.
• W2593663511 cites W2136034922 @default.
• W2593663511 cites W2139984622 @default.
• W2593663511 cites W2147540485 @default.
• W2593663511 cites W2160489474 @default.
• W2593663511 cites W2276517523 @default.
• W2593663511 cites W2282617728 @default.
• W2593663511 cites W2516453631 @default.
• W2593663511 cites W2519292185 @default.
• W2593663511 doi "https://doi.org/10.1371/journal.pmed.1002248" @default.
• W2593663511 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5330452" @default.
• W2593663511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28245243" @default.
• W2593663511 hasPublicationYear "2017" @default.
• W2593663511 type Work @default.
• W2593663511 sameAs 2593663511 @default.
• W2593663511 citedByCount "39" @default.
• W2593663511 countsByYear W25936635112017 @default.
• W2593663511 countsByYear W25936635112018 @default.
• W2593663511 countsByYear W25936635112019 @default.
• W2593663511 countsByYear W25936635112020 @default.
• W2593663511 countsByYear W25936635112021 @default.
• W2593663511 countsByYear W25936635112022 @default.
• W2593663511 countsByYear W25936635112023 @default.
• W2593663511 crossrefType "journal-article" @default.
• W2593663511 hasAuthorship W2593663511A5003818035 @default.
• W2593663511 hasAuthorship W2593663511A5006457421 @default.
• W2593663511 hasAuthorship W2593663511A5011316383 @default.
• W2593663511 hasAuthorship W2593663511A5013279353 @default.
• W2593663511 hasAuthorship W2593663511A5016791237 @default.
• W2593663511 hasAuthorship W2593663511A5018412105 @default.
• W2593663511 hasAuthorship W2593663511A5020204477 @default.

• next